| ASMQ available in Brazil, India, Malaysia, Myanmar, Tanzania, Vietnam, Niger, Burkina Faso, Thailand, Cameroon and Cambodia!
900,000 treatments distributed Included in the Essential Medicines List (EML) and Essential Medicines List for children (EMLc) of the WHO in 2013
|
 Click on the map to enlarge |
||||||||
 In March 2008, Farmanguinhos/Fiocruz successfully registered ASMQ in Brazil. The co-formulation was used by Brazilian authorities and the Malaria Programme for a large intervention study, which included over 23,000 patients, with remarkable positive results. [see results published in Malaria Journal]
April 2009 marked an important milestone for ASMQ as the first public order of treatments was completed by Brazilian government.
An active Pharmacovigilance plan is being put in place in Brazil. Admission of Farmanguinhos/Fiocruz to the PAHO Strategic Fund in April 2013 will allow procurement by South American national control programs. |
||
 Farmanguinhos/Fiocruz with support from DNDi committed to a technology transfer to the Indian manufacturer, Cipla, in order to facilitate its future availability in Southeast Asia. This transfer has been successfully achieved and the registration lots have been manufactured by Cipla at the end of 2009 – beginning of 2010.
In December 2011, ASMQ was registered in India. In 2012, it was registered in Malaysia (March) and Myanmar (September). In Vietnam, in December 2013, low strength ASMQ was registered. High strength was registered in April 2014. A comparison of ACTs has been performed in Myanmar between December 2008 and March 2009. This important study showed very favorable results for the FDC. [see results published in The Lancet Infectious Diseases] A WHO study on 45 patients was completed in Cambodia, showing overall favorable results. [see results published in Malaria Journal] A phase III trial is ongoing in Thailand on 1000 pregnant women comparing the efficacy, safety and pharmacokinetics of ASMQ FDC, DHA-PQ and artmether-lumefantrine. In March 2015, ASMQ was registered in Thailand and Cambodia. Registration is pending in Laos, Philippines, Papua New Guinea, and Indonesia. |
||
 DNDi evaluated ASMQ as an alternative antimalarial treatment for children in Africa. The general objective was to compare the efficacy and safety of ASMQ with Artenether-Lumefantrine (AM-LM) in children under the age of 5 with uncomplicated falciparum malaria in Africa through a phase IV multicentric clinical study. In 2010, the study in Burkina Faso started with 20 patients. The study was performed in Tanzania (NIMR), Kenya (KEMRI), and Burkina Faso (CNRFP). Results of the study are being prepared for publication. Read the press release about the study results.
In December 2013, ASMQ was registered in Tanzania. In 2014, it was registered in Niger (June) and Burkina Faso (September). In March 2016, ASMQ was registered in Cameroon. Registration is pending in Kenya, Ghana, Benin, Togo, Chad, Ivory Coast, Republic of Guinea, Senegal, Democratic Republic of Congo, Malawi, Congo, and Mali. |
||